The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase: Active, not recruiting; Phase 2

Conditions: Chronic Lymphocytic Leukemia (CLL)

Treatments: Drug: Venetoclax; Drug: Obinutuzumab

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04447768

20-044

Details and patient eligibility

About

This study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in people who have not received a previous treatment for their cancer.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent form.

• Ability and willingness to comply with the requirements of the study protocol.

• Age ≥18 years.

• Have documented previously untreated chronic lymphocytic leukemia according to iwCLL / WHO criteria.

• Require treatment of CLL per iwCLL guidelines.

• CIRS score ≤ 6 (patient's CLL diagnosis is not included in CIRS score).

• Eastern Cooperative Oncology Group Performance Status of 0 or 1.

• Adequate hematologic function (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by CLL per the investigator) defined as follows:

  • Hemoglobin ≥ 8 g/dL without transfusion support, unless anemia is due to marrow involvement of CLL.
  • Absolute neutrophil count ≥ 1.0 x 10^9/L.
  • Platelet count ≥ 30 x 10^9/L; in cases of thrombocytopenia clearly due to marrow involvement of CLL (per the discretion of the investigator), platelet count should be ≥ 10 x 10^9/L if there is bone marrow involvement.

• Adequate renal function, as indicated by modified Cockcroft-Gault equation (eCCR; with the use of ideal body mass [IBM] instead of mass) of > 50mL/min

• Adequate liver function, as indicated by:

  • AST or ALT ≤ 2.5 x ULN.
  • Total bilirubin ≤ 1.5 x ULN (or ≤ 5 x ULN for patients with documented Gilbert syndrome).

• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer.

  • Women must refrain from donating eggs during this same period.
  • A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (> 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
  • Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
  • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:

  • With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer. Men must refrain from donating sperm during this same period.
  • With pregnant female partners, men must remain abstinent or use a condom for the duration of the pregnancy to avoid exposing the embryo.
  • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Exclusion criteria

• Prior CLL-directed therapy. Patients may have received a brief (≤7 days) course of systemic steroids prior to initiation of study therapy for control of lymphoma-related symptoms.

• Transformation of CLL to aggressive NHL (Richter's transformation or prolymphocytic leukemia).

• Known hypersensitivity to any of the study drugs.

• History of prior malignancy, except for conditions as listed below if patients have recovered from the acute side effects incurred as a result of previous therapy:

  • Malignancies treated with curative intent and with no known active disease within 2 years
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease (no time constraint).
  • Adequately treated cervical carcinoma in situ without evidence of disease (no time constraint).
  • Surgically/adequately treated low grade, early stage, localized prostate cancer without evidence of disease (no time constraint).

• Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1.

• Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin).

• Received the following agents within 7 days prior to the first dose of venetoclax:

  • Strong and moderate CYP3A inhibitors.
  • Strong and moderate CYP3A inducers.
  • Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax.

• Clinically significant history of liver disease, including active viral or other hepatitis, current alcohol abuse, or cirrhosis

• Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) antibody

  • Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation
  • Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and should consider antiviral prophylaxis as per institutional standards.

• Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)

• Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment

• Pregnant or lactating, or intending to become pregnant during the study

  °Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study drug per institutional standards.

• Recent major surgery (within 4 weeks prior to the start of Cycle 1, Day 1) other than for diagnosis.

• Inability to swallow a large number of tablets.

• Malabsorption syndrome or other condition that precludes enteral route of administration. This is subject to investigator discretion.

• Known allergy to both xanthine oxidase inhibitors and rasburicase.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Venetoclax and Obinutuzumab

Experimental group

Description:

All patients will receive a minimum of 9 cycles (cycle = 28 days) of therapy with venetoclax and obinutuzumab during the treatment period. For patients who remain MRD positive at Cycle 9 of therapy, an additional 12 cycles of venetoclax monotherapy will be given.

Treatment:

Drug: Obinutuzumab

Drug: Venetoclax